Chandana Konduru, MD
Endocrinology, Diabetes & Metabolism · Arlington, TXNPI 1669423281
Payments from drug & device makers
Across 542 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Mannkind Corporation$917
- Novo Nordisk$819
- Bayer$735
- Abbott$734
- AstraZeneca$733
- plus $4K from 33 others
What the payments were for
- Food & beverage$9,48499%
- Education$531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 89 | $1,467 |
| Mannkind Corporation | 59 | $917 |
| Novo Nordisk | 42 | $819 |
| Bayer | 33 | $735 |
| Abbott | 63 | $734 |
| AstraZeneca(2 entities) | 42 | $733 |
| Medtronic(2 entities) | 14 | $476 |
| Amgen | 14 | $436 |
| Boehringer Ingelheim | 24 | $398 |
| Dexcom, Inc. | 13 | $325 |
| Insulet Corporation | 17 | $323 |
| Xeris Pharmaceuticals, Inc. | 23 | $312 |
| AbbVie | 21 | $310 |
| Merck | 22 | $288 |
| Cequr Corporation | 4 | $166 |
| IBSA Pharma Inc. | 8 | $128 |
| Sanofi-aventis U.S. LLC | 6 | $115 |
| Sequel Med Tech, LLC | 5 | $100 |
| Zealand Pharma US, Inc. | 5 | $92 |
| Ascendis Pharma Endocrinology Inc | 4 | $83 |
| Tandem Diabetes Care, Inc. | 3 | $66 |
| Intuity Medical Inc | 4 | $66 |
| BD | 3 | $58 |
| Corcept Therapeutics | 2 | $47 |
| Amneal Pharmaceuticals LLC | 3 | $47 |
| Valeritas, Inc. | 3 | $44 |
| Johnson & Johnson | 3 | $37 |
| Radius Health, Inc. | 1 | $25 |
| Ascensia Diabetes Care US Inc. | 1 | $23 |
| Amarin Pharma, Inc. | 2 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Lifescan, Inc. | 1 | $21 |
| Tolmar, Inc. | 1 | $17 |
| Vistapharm, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Pfizer | 1 | $13 |
| Alvogen Inc | 1 | $12 |
| BETA Bionics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$497
- Minimed 670G System$266
- EVENITY$242
- AFREZZA$115
- Tresiba$113
How this compares
$9,537 in reported general payments places this provider in the 60th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 389 | $747,846 |
| TrulicityDulaglutide | 240 | $436,930 |
| MounjaroTirzepatide | 149 | $303,741 |
| JardianceEmpagliflozin | 201 | $273,416 |
| FarxigaDapagliflozin Propanediol | 109 | $135,021 |
| Tresiba Flextouch U-100Insulin Degludec | 158 | $123,240 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 81 | $75,845 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 55 | $67,002 |
| Tresiba Flextouch U-200Insulin Degludec | 55 | $66,800 |
| Humalog Kwikpen U-200Insulin Lispro | 32 | $54,507 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 13 | $48,688 |
| Humalog Kwikpen U-100Insulin Lispro | 107 | $46,318 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 25 | $41,742 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 24 | $36,317 |
| JanuviaSitagliptin Phosphate | 34 | $32,713 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $819 | $764,945412 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,467 | $760,548446 claims |
| Boehringer IngelheimJardiance | $398 | $273,416201 claims |
| AstraZenecaFarxiga | $733 | $135,021109 claims |
| MerckJanuvia, Janumet Xr | $288 | $45,77446 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $115 | $41,74225 claims |
| Alvogen IncTeriparatide | $12 | $19,53611 claims |
| AbbVieSynthroid | $310 | $12,388109 claims |
| BayerKerendia | $735 | $9,15212 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $47 | $5,282470 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Arlington
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
- Ildiko LingvayDallas$8.2M
- Eduardo LunaEdinburg$7.6M
- Thomas BlevinsAustin$7.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.